Primary prevention of stroke: RESPECT

Abstract

RESPECT is a multi-centre, randomized, double-blind, placebo-controlled, parallel group comparison study of cerivastatin sodium (0.4 mg and 0.8 mg once daily) versus placebo, evaluating whether cerivastatin (HMG-CoA reductase inhibitor) is effective in primary prevention of stroke in elderly patients (65-80 years of age) that are at risk for stroke but who do not have coronary heart disease.